Larimar Therapeutics, Inc.
LRMRLarimar Therapeutics, Inc. in brief
Larimar Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Bala Cynwyd, Pennsylvania, USA. Its market value was $246 M on 26 October 2026, which makes it the 15,536th largest listed company in the world and the 3,023rd largest in the USA on this site. It employs about 71 people and Carole Ben-Maimon is its chief executive. Its shares trade under the symbol LRMR (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Larimar Therapeutics, Inc.
We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide technology platform. Our lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver frataxin, an essential protein, to the mitochondria of patients with Friedreich's ataxia. FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Currently, there are no treatment options that address the core deficit of FA, low levels of FXN. Nomlabofusp represents the first potential therapy designed to systemically increase FXN levels in patients with FA.
From the company's annual report filed with the US SEC: read the report
Larimar Therapeutics, Inc. timeline
- 2006
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2014
- 🔔Initial public offering as Zafgen IncFinal prospectus filed with the SEC on 19 June 2014; shares registered for exchange trading on 18 June 2014.
- 2020
- ✎Renamed Larimar Therapeutics, Inc.Formerly Zafgen Inc.
Events of Larimar Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,991 (Jan 2022) · #3,736 (Dec 2022) · #3,732 (Jul 2023) · #3,194 (Jan 2024) · #1,296 (Mar 2026) · #2,596 (Aug 2026) · #3,063 (Oct 2026) · #3,027 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 3.1×
- Free cash flow yield
- -46.1%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -212.2%
- Liabilities / assets
- 46.5%
- Net debt
- $14M
- Profit per employee
- $-2.3 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-173M | $-166M | — |
| Dec 2024 | — | — | $-91M | $-81M | — |
| Dec 2023 | — | — | $-42M | $-37M | — |
| Dec 2022 | — | — | $-37M | $-35M | — |
| Dec 2021 | — | — | $-50M | $-51M | — |
| Dec 2020 | — | — | $-43M | $-42M | — |
| Dec 2019 | — | — | $-23M | $-23M | — |
| Dec 2018 | — | — | $-61M | $-61M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-113M | $0M | $-113M | — | — |
| Dec 2024 | $-71M | $1M | $-71M | $-1.32 | — |
| Dec 2023 | $-33M | $0M | $-34M | $-0.84 | — |
| Dec 2022 | $-28M | $0M | $-28M | $-1.37 | — |
| Dec 2021 | $-42M | $0M | $-42M | $-2.95 | — |
| Dec 2020 | $-42M | $0M | $-42M | $-3.57 | — |
| Dec 2019 | $-23M | $0M | $-23M | $-3.80 | — |
| Dec 2018 | $-51M | $0M | $-52M | $-1.90 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-33M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 9, 20268-KCurrent reportResults of operations · Other events
- Sep 29, 20268-KCurrent reportDirectors or officers changed
- Aug 4, 202610-QQuarterly report · period to Jun 2026
- Aug 4, 20268-KCurrent reportResults of operations · Other events
- Jun 29, 20268-KCurrent reportOther events
- May 19, 20268-KCurrent reportShareholder vote
- May 14, 202610-QQuarterly report · period to Mar 2026
- May 14, 20268-KCurrent reportResults of operations · Other events
- Apr 20, 2026DEF 14AProxy statement
- Mar 19, 202610-KAnnual report · period to Dec 2025
- Mar 19, 20268-KCurrent reportResults of operations
- Mar 9, 20268-KCurrent reportOther events
Official filings of Larimar Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-173 M
- Net income
- $-166 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $146 M
- Total liabilities
- $68 M
- Total equity
- $78 M
As of December-2025
Top 100 institutional investors in Larimar Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Deerfield Management Company, L.P. | 35,606,974 | 0 (0.00%) | 34.28% | $114 M | Nov 16, 2026 |
| 2 | Blue Owl Capital Holdings LP | 9,923,904 | +760,747 (+8.30%) | 9.55% | $32 M | Nov 13, 2026 |
| 3 | RTW Investments, LP | 5,820,891 | +3,254,892 (+126.85%) | 5.60% | $19 M | Nov 16, 2026 |
| 4 | BlackRock, Inc. | 5,770,174 | +92,139 (+1.62%) | 5.55% | $18 M | Nov 13, 2026 |
| 5 | Defilade Capital Management, L.P. | 4,934,439 | +1,264,304 (+34.45%) | 4.75% | $16 M | Nov 16, 2026 |
| 6 | Driehaus Capital Management LLC | 3,128,669 | -34,754 (-1.10%) | 3.01% | $10 M | Nov 16, 2026 |
| 7 | Vanguard Capital Management LLC | 2,974,901 | 0 (0.00%) | 2.86% | $10 M | Nov 13, 2026 |
| 8 | Goldman Sachs Group Inc | 2,971,385 | +1,218,475 (+69.51%) | 2.86% | $9 M | Nov 16, 2026 |
| 9 | AQR Capital Management LLC | 2,240,623 | -130,791 (-5.52%) | 2.16% | $7 M | Nov 16, 2026 |
| 10 | Marshall Wace, LLP | 2,195,954 | +183,496 (+9.12%) | 2.11% | $7 M | Nov 13, 2026 |
| 11 | DAFNA Capital Management LLC | 1,888,155 | -120,009 (-5.98%) | 1.82% | $6 M | Nov 16, 2026 |
| 12 | Bank Of America Corp /de/ | 1,871,368 | +1,823,765 (+3831.20%) | 1.80% | $6 M | Nov 16, 2026 |
| 13 | AIGH Capital Management LLC | 1,850,000 | New | 1.78% | $6 M | Nov 2, 2026 |
| 14 | Geode Capital Management, LLC | 1,743,938 | +64,935 (+3.87%) | 1.68% | $6 M | Nov 6, 2026 |
| 15 | Millennium Management LLC | 1,669,047 | +336,010 (+25.21%) | 1.61% | $5 M | Nov 16, 2026 |
| 16 | State Street Corp | 1,453,632 | +41,828 (+2.96%) | 1.40% | $5 M | Nov 12, 2026 |
| 17 | Qube Research & Technologies Ltd | 1,414,664 | -226,378 (-13.79%) | 1.36% | $5 M | Nov 13, 2026 |
| 18 | Vanguard Portfolio Management LLC | 1,413,686 | +10,514 (+0.75%) | 1.36% | $5 M | Nov 13, 2026 |
| 19 | Woodline Partners LP | 1,400,850 | 0 (0.00%) | 1.35% | $4 M | Nov 16, 2026 |
| 20 | Dimensional Fund Advisors LP | 1,129,697 | +168,614 (+17.54%) | 1.09% | $4 M | Nov 4, 2026 |
| 21 | FMR LLC | 1,093,227 | +155,859 (+16.63%) | 1.05% | $3 M | Nov 10, 2026 |
| 22 | Sphera Funds Management LTD. | 1,035,004 | +109,000 (+11.77%) | 1.00% | $3 M | Nov 16, 2026 |
| 23 | Ghisallo Capital Management LLC | 750,000 | New | 0.72% | $2 M | Nov 16, 2026 |
| 24 | Alyeska Investment Group, L.P. | 617,211 | 0 (0.00%) | 0.59% | $2 M | Nov 16, 2026 |
| 25 | Hennion & Walsh Asset Management, Inc. | 570,361 | +173,635 (+43.77%) | 0.55% | $2 M | Oct 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | D. E. Shaw & Co., Inc. | 568,598 | New | 0.55% | $2 M | Nov 16, 2026 |
| 27 | Prudential Financial Inc | 559,323 | +430,900 (+335.53%) | 0.54% | $2 M | Nov 16, 2026 |
| 28 | Northern Trust Corp | 544,369 | -5,897 (-1.07%) | 0.52% | $2 M | Nov 16, 2026 |
| 29 | Vanguard Fiduciary Trust Co | 446,659 | -1,509 (-0.34%) | 0.43% | $1 M | Nov 13, 2026 |
| 30 | SummitTX Capital, L.P. | 406,301 | +54,017 (+15.33%) | 0.39% | $1 M | Nov 16, 2026 |
| 31 | Jpmorgan Chase & Co | 309,818 | -18,197 (-5.55%) | 0.30% | $1 M | Nov 12, 2026 |
| 32 | Burkehill Global Management, LP | 300,000 | 0 (0.00%) | 0.29% | $1 M | Nov 16, 2026 |
| 33 | Cerity Partners LLC | 274,814 | +3,232 (+1.19%) | 0.26% | $1 M | Nov 13, 2026 |
| 34 | Gem Investment Advisors, LLC | 262,199 | -57,320 (-17.94%) | 0.25% | $1 M | Nov 13, 2026 |
| 35 | Wellington Management Group LLP | 242,460 | New | 0.23% | $1 M | Nov 16, 2026 |
| 36 | ADAR1 Capital Management, LLC | 237,735 | -35,010 (-12.84%) | 0.23% | $1 M | Nov 16, 2026 |
| 37 | Two Sigma Investments, LP | 236,133 | 0 (0.00%) | 0.23% | $1 M | Nov 16, 2026 |
| 38 | UBS Group AG | 216,387 | +72,061 (+49.93%) | 0.21% | $1 M | Nov 10, 2026 |
| 39 | Morgan Stanley | 213,988 | +127,130 (+146.37%) | 0.21% | $1 M | Nov 13, 2026 |
| 40 | Charles Schwab Investment Management Inc | 206,986 | +17 (+0.01%) | 0.20% | $1 M | Nov 16, 2026 |
| 41 | Susquehanna Portfolio Strategies, LLC | 203,160 | +38,004 (+23.01%) | 0.20% | $1 M | Nov 16, 2026 |
| 42 | Federated Hermes, Inc. | 189,065 | +98,215 (+108.11%) | 0.18% | $1 M | Nov 12, 2026 |
| 43 | Diadema Partners LP | 185,705 | +39,068 (+26.64%) | 0.18% | $1 M | Nov 16, 2026 |
| 44 | Renaissance Technologies LLC | 184,043 | -113,400 (-38.12%) | 0.18% | $1 M | Nov 12, 2026 |
| 45 | Creative Planning | 176,685 | +59,884 (+51.27%) | 0.17% | $1 M | Nov 2, 2026 |
| 46 | Bank of New York Mellon Corp | 143,960 | +5,129 (+3.69%) | 0.14% | $0 M | Nov 5, 2026 |
| 47 | Nuveen, LLC | 140,788 | -754,516 (-84.27%) | 0.14% | $0 M | Nov 10, 2026 |
| 48 | Invesco Ltd. | 135,459 | +976 (+0.73%) | 0.13% | $0 M | Nov 12, 2026 |
| 49 | Gsa Capital Partners LLP | 121,083 | +71,005 (+141.79%) | 0.12% | $0 M | Nov 16, 2026 |
| 50 | Ieq Capital, LLC | 116,743 | -86,620 (-42.59%) | 0.11% | $0 M | Nov 10, 2026 |
| 51 | Susquehanna International Group, LLP | 98,161 | -46,267 (-32.03%) | 0.09% | $0 M | Nov 16, 2026 |
| 52 | Bridgeway Capital Management, LLC | 90,132 | +48,916 (+118.68%) | 0.09% | $0 M | Nov 16, 2026 |
| 53 | Deutsche Bank AG\ | 88,907 | -7,516 (-7.79%) | 0.09% | $0 M | Nov 6, 2026 |
| 54 | Empowered Funds, LLC | 83,832 | New | 0.08% | $0 M | Nov 13, 2026 |
| 55 | Alliancebernstein L.P. | 82,830 | -25,390 (-23.46%) | 0.08% | $0 M | Nov 16, 2026 |
| 56 | Rhumbline Advisers | 80,307 | +8,419 (+11.71%) | 0.08% | $0 M | Nov 10, 2026 |
| 57 | Mariner, LLC | 74,119 | -40,326 (-35.24%) | 0.07% | $0 M | Nov 12, 2026 |
| 58 | Citadel Advisors LLC | 66,377 | -1,390,448 (-95.44%) | 0.06% | $0 M | Nov 16, 2026 |
| 59 | Squarepoint Ops LLC | 65,893 | -47,581 (-41.93%) | 0.06% | $0 M | Nov 9, 2026 |
| 60 | XTX Topco Ltd | 60,992 | +5,783 (+10.47%) | 0.06% | $0 M | Nov 16, 2026 |
| 61 | Price T Rowe Associates Inc /MD/ | 54,629 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 62 | Quadrature Capital Ltd | 54,531 | New | 0.05% | $0 M | Nov 13, 2026 |
| 63 | Mercer Global Advisors Inc /adv | 53,946 | -14,988 (-21.74%) | 0.05% | $0 M | Nov 16, 2026 |
| 64 | Axq Capital, LP | 52,458 | New | 0.05% | $0 M | Nov 12, 2026 |
| 65 | WINTON GROUP Ltd | 51,600 | -800 (-1.53%) | 0.05% | $0 M | Nov 12, 2026 |
| 66 | Acadian Asset Management LLC | 50,655 | -6,788 (-11.82%) | 0.05% | $0 M | Nov 9, 2026 |
| 67 | Persistent Asset Partners Ltd | 47,297 | +9,923 (+26.55%) | 0.05% | $0 M | Nov 13, 2026 |
| 68 | Wealth Enhancement Advisory Services, LLC | 41,974 | -21,706 (-34.09%) | 0.04% | $0 M | Oct 13, 2026 |
| 69 | Next Level Private LLC | 41,700 | 0 (0.00%) | 0.04% | $0 M | Oct 20, 2026 |
| 70 | Fi3 FINANCIAL ADVISORS, LLC | 39,342 | +36,427 (+1249.64%) | 0.04% | $0 M | Nov 18, 2026 |
| 71 | CIBC World Market Inc. | 38,000 | -15,000 (-28.30%) | 0.04% | $0 M | Nov 10, 2026 |
| 72 | HighTower Advisors, LLC | 37,576 | -122 (-0.32%) | 0.04% | $0 M | Nov 10, 2026 |
| 73 | Strs Ohio | 37,200 | +10,700 (+40.38%) | 0.04% | $0 M | Oct 30, 2026 |
| 74 | Canada Pension Plan Investment Board | 36,900 | -22,800 (-38.19%) | 0.04% | $0 M | Nov 16, 2026 |
| 75 | Barclays PLC | 35,087 | +9,130 (+35.17%) | 0.03% | $0 M | Nov 6, 2026 |
| 76 | Velan Capital Investment Management LP | 33,000 | 0 (0.00%) | 0.03% | $0 M | Nov 16, 2026 |
| 77 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 32,277 | +1,625 (+5.30%) | 0.03% | $0 M | Nov 16, 2026 |
| 78 | Wells Fargo & Company/mn | 31,611 | -30,492 (-49.10%) | 0.03% | $0 M | Nov 16, 2026 |
| 79 | MetLife Investment Management, LLC | 31,085 | -8,713 (-21.89%) | 0.03% | $0 M | Nov 16, 2026 |
| 80 | Cary Street Partners Financial LLC | 30,000 | -55,000 (-64.71%) | 0.03% | $0 M | Nov 12, 2026 |
| 81 | Russell Investments Group, Ltd. | 27,364 | 0 (0.00%) | 0.03% | $0 M | Nov 6, 2026 |
| 82 | Caption Management, LLC | 24,033 | -168,985 (-87.55%) | 0.02% | $0 M | Nov 16, 2026 |
| 83 | Commonwealth Equity Services, LLC | 23,067 | 0 (0.00%) | 0.02% | $0 M | Nov 2, 2026 |
| 84 | Vanguard Global Advisers, LLC | 21,348 | +301 (+1.43%) | 0.02% | $0 M | Nov 13, 2026 |
| 85 | Walleye Trading LLC | 20,000 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 86 | American Century Companies Inc | 19,537 | -6,930 (-26.18%) | 0.02% | $0 M | Nov 12, 2026 |
| 87 | Manufacturers Life Insurance Company, The | 19,043 | -477 (-2.44%) | 0.02% | $0 M | Nov 13, 2026 |
| 88 | BNP Paribas Financial Markets | 18,959 | +8,073 (+74.16%) | 0.02% | $0 M | Nov 12, 2026 |
| 89 | China Universal Asset Management Co., Ltd. | 18,955 | +2,422 (+14.65%) | 0.02% | $0 M | Oct 28, 2026 |
| 90 | Vanguard Personalized Indexing Management, LLC | 18,348 | -201 (-1.08%) | 0.02% | $0 M | Nov 16, 2026 |
| 91 | Ethic Inc. | 17,749 | -130 (-0.73%) | 0.02% | $0 M | Nov 3, 2026 |
| 92 | Captrust Financial Advisors | 17,073 | -8,138 (-32.28%) | 0.02% | $0 M | Nov 12, 2026 |
| 93 | Police & Firemen's Retirement System of New Jersey | 15,976 | +2,250 (+16.39%) | 0.02% | $0 M | Nov 9, 2026 |
| 94 | Cherry Tree Wealth Management, LLC | 15,264 | 0 (0.00%) | 0.01% | $0 M | Oct 15, 2026 |
| 95 | Quantinno Capital Management LP | 15,009 | New | 0.01% | $0 M | Nov 13, 2026 |
| 96 | Brevan Howard Capital Management LP | 13,601 | -5,903 (-30.27%) | 0.01% | $0 M | Nov 16, 2026 |
| 97 | Voya Investment Management LLC | 13,105 | 0 (0.00%) | 0.01% | $0 M | Nov 10, 2026 |
| 98 | Keystone Financial Group | 13,000 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 99 | ProShare Advisors LLC | 11,960 | -165 (-1.36%) | 0.01% | $0 M | Oct 29, 2026 |
| 100 | Hudson Bay Capital Management LP | 11,000 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
Mutual funds holding Larimar Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 2.21 M | $7 M | 2.1% | <0.01% | −5.6% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.72 M | $5 M | 1.7% | <0.01% | +47% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 726,517 | $3 M | 0.70% | <0.01% | +55% | Jul 31, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 659,133 | $3 M | 0.63% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 814,618 | $2 M | 0.78% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 757,603 | $2 M | 0.73% | <0.01% | +58% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 699,471 | $2 M | 0.67% | <0.01% | +52% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 625,151 | $2 M | 0.60% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 340,789 | $1 M | 0.33% | <0.01% | +7.8% | Jul 31, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 370,517 | $1 M | 0.36% | 0.01% | +5.7% | Jun 30, 2026 |
| 🇺🇸 Driehaus Micro Cap Growth FundDriehaus Capital Management LLC | 338,986 | $1 M | 0.33% | 0.17% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 243,097 | $1 M | 0.23% | <0.01% | +1.3% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 218,451 | $1 M | 0.21% | <0.01% | −1.4% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 223,612 | $1 M | 0.22% | 0.04% | +88% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 162,130 | $1 M | 0.16% | <0.01% | +61% | Jul 31, 2026 |
| 🇺🇸 Adara Smaller Companies FundRBB Fund, Inc. | 164,782 | $1 M | 0.16% | 0.07% | +28% | May 31, 2026 |
| 🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc. | 183,018 | $1 M | 0.18% | 0.04% | −5.7% | Jun 30, 2026 |
| 🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc. | 152,105 | $1 M | 0.15% | 0.03% | new | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 134,273 | $1 M | 0.13% | <0.01% | +71% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 105,245 | $0 M | 0.10% | <0.01% | +753% | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 101,888 | $0 M | 0.10% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 124,437 | $0 M | 0.12% | <0.01% | +78% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 88,924 | $0 M | 0.09% | <0.01% | +56% | Jul 31, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 109,890 | $0 M | 0.11% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 99,391 | $0 M | 0.10% | 0.04% | +106% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 73,253 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC | 76,263 | $0 M | 0.07% | 0.06% | new | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 72,450 | $0 M | 0.07% | <0.01% | +42% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 63,368 | $0 M | 0.06% | <0.01% | +7.2% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 62,068 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 SIMT Small Cap FundSEI Institutional Managed Trust | 66,820 | $0 M | 0.06% | 0.04% | +1128% | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 57,657 | $0 M | 0.06% | 0.03% | +18% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 62,127 | $0 M | 0.06% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 59,570 | $0 M | 0.06% | <0.01% | +49% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 44,839 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Federated Hermes MDT Small Cap Core ETFFederated Advisory Services Company | 47,062 | $0 M | 0.05% | 0.06% | +32% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 49,400 | $0 M | 0.05% | <0.01% | +58% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 48,650 | $0 M | 0.05% | <0.01% | +68% | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 37,235 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC | 45,021 | $0 M | 0.04% | 0.04% | −14% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 35,912 | $0 M | 0.03% | <0.01% | +66% | Jul 31, 2026 |
| 🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company | 37,280 | $0 M | 0.04% | 0.05% | −11% | May 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 33,404 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 36,214 | $0 M | 0.03% | <0.01% | −0.7% | May 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 31,780 | $0 M | 0.03% | <0.01% | +56% | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 39,310 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 34,916 | $0 M | 0.03% | 0.07% | no change | Jun 30, 2026 |
| 🇺🇸 Siit Small Cap FundSEI INVESTMENTS MANAGEMENT CORPORATION | 30,360 | $0 M | 0.03% | 0.05% | +310% | May 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 34,598 | $0 M | 0.03% | <0.01% | +40% | Jun 30, 2026 |
| 🇺🇸 Siit Small Cap II FundSEI INVESTMENTS MANAGEMENT CORPORATION | 29,512 | $0 M | 0.03% | 0.04% | +323% | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 29,674 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P. | 23,226 | $0 M | 0.02% | 0.03% | +104% | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 22,859 | $0 M | 0.02% | <0.01% | −75% | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 24,913 | $0 M | 0.02% | <0.01% | −66% | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 22,456 | $0 M | 0.02% | <0.01% | +54% | Jul 31, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC | 27,652 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 26,862 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 20,086 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 21,587 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 22,565 | $0 M | 0.02% | <0.01% | +46% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 15,942 | $0 M | 0.02% | <0.01% | +215% | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 19,843 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 19,794 | $0 M | 0.02% | <0.01% | +58% | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 19,500 | $0 M | 0.02% | <0.01% | +27% | Jun 30, 2026 |
| 🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP | 14,494 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 17,440 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 16,968 | $0 M | 0.02% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 12,923 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 15,087 | $0 M | 0.01% | 0.02% | +70% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 14,793 | $0 M | 0.01% | <0.01% | +2.0% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 11,721 | $0 M | 0.01% | <0.01% | +70% | Jul 31, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 14,554 | $0 M | 0.01% | <0.01% | +49% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 14,486 | $0 M | 0.01% | <0.01% | +66% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 11,156 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 9,678 | $0 M | <0.01% | <0.01% | +53% | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 10,448 | $0 M | 0.01% | <0.01% | +59% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 10,036 | $0 M | <0.01% | <0.01% | +83% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 10,044 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 7,825 | $0 M | <0.01% | <0.01% | +34% | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 8,917 | $0 M | <0.01% | <0.01% | +69% | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 8,413 | $0 M | <0.01% | <0.01% | +59% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 6,900 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 6,129 | $0 M | <0.01% | <0.01% | +58% | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 5,850 | $0 M | <0.01% | <0.01% | +0.2% | Jul 31, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 5,742 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 6,643 | $0 M | <0.01% | <0.01% | +0.8% | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 6,055 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 4,731 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP | 4,394 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 5,323 | $0 M | <0.01% | <0.01% | +52% | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 4,692 | $0 M | <0.01% | <0.01% | +52% | Jun 30, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 4,664 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 4,121 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 3,277 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 2,781 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 3,171 | $0 M | <0.01% | <0.01% | +2.4% | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 3,046 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 2,221 | $0 M | <0.01% | <0.01% | +5.6% | May 31, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 1,788 | $0 M | <0.01% | <0.01% | −5.2% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 1,755 | $0 M | <0.01% | <0.01% | −41% | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Larimar Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Russell ClaytonChief Medical Officer | Buy | +3,322 | $3.010 | $10 K | 74,765 | Form 4 |
| filed | Jeffrey W. ShermanDirector | Buy | +3,289 | $3.058 | $10 K | 8,289 | Form 4 |
| filed | Thomas Edward HamiltonDirector | Buyindirect | +70,000 | $2.673 | $187 K | 70,000 | Form 4 |
| filed | Joseph TruittDirector | Buy | +3,500 | $2.798 | $10 K | 6,250 | Form 4 |
| filed | Frank E. ThomasDirector | Buy | +8,000 | $2.725 | $22 K | 15,000 | Form 4 |
| filed | Carole Ben-MaimonPresident and CEO, Director | Buy | +18,050 | $2.768 | $50 K | 386,326 | Form 4 |
| filed | John B. Harlow Jr.President and COO | Buy | +17,800 | $2.804 | $50 K | 67,800 | Form 4 |
| filed | Gopi ShankarChief Development Officer | Buy | +5,000 | $2.710 | $14 K | 81,443 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Larimar Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 6.28-for-1 split in the period to
Trading halts
- 2024-12-16 14:54 UTC, code LUDP, resumed 15:04 UTC
- 2024-12-16 14:45 UTC, code LUDP, resumed 14:50 UTC
- 2024-12-16 14:36 UTC, code LUDP, resumed 14:41 UTC
Fails to deliver
- : 435 shares at $2.35
- : 431 shares at $2.27
- : 105 shares at $2.12
- : 443 shares at $1.99
- : 49,053 shares at $2.16
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Larimar Therapeutics, Inc. scorecard#
Passes 1 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 26, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.1×Price to book 3.1× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-46.1%Free cash flow is -46.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$166 M-$166 M in fiscal 2025 against -$42 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$166 MNet income -$166 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-132.6%-132.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities2.2×Current ratio 2.19 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Larimar Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | — | — | — | — | 0—— | 0—— | 0—— | 0—— | |
| Research and development | 154+110%— | 73+165%— | 28+14.1%— | 24−36.8%— | 38+22.3%— | 31+51.1%— | 21r24−56.6%— | 48+17.4%— | 41+2.3%— | 40—— | |
| General and administrative | 18+3.8%— | 18+25.0%— | 14+14.8%— | 12+1.7%— | 12+5.9%— | 11+370%— | 2.4r16−81.6%— | 13+8.5%— | 12−33.5%— | 18—— | |
| Operating expenses | 172+89.8%— | 91+118%— | 42+14.3%— | 37−27.6%— | 50+17.9%— | 43+84.4%— | 23r46−62.0%— | 61+15.3%— | 53−9.0%— | 58—— | |
| Operating income | −172—— | −91—— | −42—— | −37—— | −50—— | −43—— | −23r−46—— | −61—— | −53—— | −58—— | |
| Interest and finance income | — | — | — | — | — | — | 2.0+5.3%— | 1.9+89.7%— | 1.0—— | — | |
| Interest expense and finance costs | — | — | — | — | — | — | 1.8−7.0%— | 1.9+1050%— | 0.2−68.8%— | 0.5—— | |
| Other non-operating income (expense) | 6.8−33.7%— | 10+114%— | 4.8+311%— | 1.2—— | −0.2−153%— | 0.3+293%— | 0.1r0.2—— | −0.2−125%— | 1.0+180%— | 0.3—— | |
| Income before tax | −166—— | −81—— | −37—— | −35—— | −51—— | −42—— | −23r−45—— | −61—— | −52—— | −58—— | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | |
| Net income including minority interests | −166—— | −81—— | −37—— | −35—— | −51—— | −42—— | −23r−45—— | −61—— | −52—— | −58—— | |
| Net income attributable to shareholders | −166—— | −81—— | −37—— | −35—— | −51—— | −42—— | −23r−45—— | −61—— | −52—— | −58—— | |
| Earnings per share, basic | — | -1.32—— | -0.84—— | -1.37—— | -2.95—— | -3.57—— | -3.80r-1.22—— | -1.90—— | -1.90—— | -2.12—— | |
| Earnings per share, diluted | — | -1.32—— | -0.84—— | -1.37—— | -2.95—— | -3.57—— | -3.80r-1.22—— | -1.90—— | -1.90—— | -2.12—— | |
| Shares, weighted average (basic) | — | 61+39.5%— | 44+70.4%— | 26+50.1%— | 17+44.4%— | 12—— | — | — | — | — | |
| Shares, weighted average (diluted) | — | 61+39.5%— | 44+70.4%— | 26+50.1%— | 17+44.4%— | 12+95.1%— | 6.1r37−81.1%— | 32+17.5%— | 27+0.5%— | 27—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 85+157%58.6% | 33+24.2%16.6% | 27−0.3%27.9% | 27−61.7%21.2% | 70+2.9%89.1% | 68+6654%65.1% | 1.0r27−98.0%19.4% | 49+21.0%40.5% | 41+26.0%38.6% | 32—24.6% | |
| Short-term investments | 51−65.8%35.3% | 150+150%75.0% | 60−34.5%62.6% | 92—72.5% | — | 24−43.1%23.4% | 43−37.4%828% | 69+12.2%56.5% | 61−36.7%58.1% | 97—73.6% | |
| Other current assets | 5.2−56.4%3.5% | 12+250%5.9% | 3.4+46.5%3.5% | 2.3+9.7%1.8% | 2.1−60.4%2.7% | 5.3+42.0%5.1% | 3.7r1.0+116%71.9% | 1.7−10.3%1.4% | 1.9+41.9%1.8% | 1.4—1.0% | |
| Current assets | 142−27.3%97.4% | 195+117%97.5% | 90−25.3%94.0% | 121+67.2%95.5% | 72−26.3%91.8% | 98+1962%93.6% | 4.8r72−96.1%91.3% | 121+15.6%99.6% | 105−19.8%99.4% | 131—99.5% | |
| Property, plant and equipment | 0.6−29.4%0.4% | 0.9+28.8%0.4% | 0.7−17.7%0.7% | 0.8−20.8%0.7% | 1.0+0.9%1.3% | 1.0+280%1.0% | 0.3r0.8−26.9%5.3% | 0.4−29.0%0.3% | 0.5−20.1%0.5% | 0.7—0.5% | |
| Right-of-use (leased) assets | 2.1−27.1%1.4% | 2.8−7.8%1.4% | 3.1+7.7%3.2% | 2.9−16.1%2.3% | 3.4−13.5%4.3% | 3.9+4424%3.8% | 0.1r7.1—1.7% | — | — | — | |
| Total assets | 146−27.2%100% | 200+109%100% | 96−24.1%100% | 126+60.7%100% | 79−24.9%100% | 105+1913%100% | 5.2r81−95.7%100% | 122+15.4%100% | 106−19.8%100% | 132—100% | |
| Accounts payable | 5.2+115%3.6% | 2.4+88.9%1.2% | 1.3−23.9%1.3% | 1.7+1.6%1.3% | 1.7−37.0%2.1% | 2.6−25.6%2.5% | 3.5r0.6−1.4%68.0% | 3.6+18.9%2.9% | 3.0+17.4%2.9% | 2.6—2.0% | |
| Current liabilities | 65+166%44.4% | 24+156%12.2% | 9.5−11.2%9.9% | 11+21.0%8.5% | 8.8−1.6%11.2% | 9.0+52.5%8.6% | 5.9r12−55.7%113% | 13+82.4%10.9% | 7.3−26.3%6.9% | 9.9—7.5% | |
| Lease liabilities (non-current) | 3.0−27.0%2.0% | 4.1−13.8%2.0% | 4.7−1.8%4.9% | 4.8−11.3%3.8% | 5.4−9.9%6.9% | 6.0−7.0%5.7% | 6.5—124% | — | — | — | |
| Total liabilities | 68+138%46.5% | 28+99.9%14.2% | 14−8.3%14.8% | 16+8.8%12.3% | 14−4.9%18.1% | 15+154%14.3% | 5.9r27−79.3%113% | 28+4.4%23.4% | 27+176%25.9% | 9.9—7.5% | |
| Retained earnings | −435—−298% | −269—−134% | −189—−197% | −152—−120% | −116—−148% | −66—−62.7% | −23r−396—−445% | −351—−288% | −290—−274% | −238—−180% | |
| Shareholders' equity | 78−54.6%53.5% | 172+110%85.8% | 82−26.3%85.2% | 111+72.2%87.7% | 64−28.2%81.9% | 90—85.7% | −0.7r54−124%−13.3% | 2.9r93−96.3%2.4% | 78−35.7%74.1% | 122—92.5% | |
| Total liabilities and equity | 146−27.2%100% | 200+109%100% | 96−24.1%100% | 126+60.7%100% | 79−24.9%100% | 105+1913%100% | 5.2r81−95.7%100% | 122+15.4%100% | 106−19.8%100% | 132—100% | |
| Shares outstanding | 83+30.2%— | 64+45.3%— | 44+1.5%— | 43+144%— | 18+15.2%— | 15+152%— | 6.1r37−83.7%— | 37+35.6%— | 27+0.6%— | 27—— | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 7.0−20.4%— | 8.8+15.5%— | 7.6+15.0%— | 6.6+20.9%— | 5.5+153%— | 2.2+1575%— | 0.1r5.5−98.7%— | 9.6+16.0%— | 8.3−17.9%— | 10—— | |
| Cash from operating activities | −113—— | −71—— | −33—— | −28—— | −42—— | −42—— | −23r−41—— | −51—— | −44—— | −52—— | |
| Capital expenditure | −0.1—— | −0.5—— | −0.2—— | −0.1—— | −0.3—— | −0.1—— | −0.1r−0.8—— | −0.1—— | −0.1—— | −0.7—— | |
| Cash from investing activities | 100—— | −85−356%— | 33—— | −91−476%— | 24+41.4%— | 17—— | −0.1r25—— | −6.9−119%— | 36−30.7%— | 51—— | |
| Shares issued | 65−59.8%— | 162—— | — | 75+278%— | 20−73.7%— | 76—— | — | 65—— | — | — | |
| Cash from financing activities | 65−59.8%— | 162+539510%— | 0.0−100.0%— | 75+278%— | 20−78.8%— | 94+383%— | 19r−5.3−71.0%— | 67+304%— | 17—— | −2.7—— | |
| Change in cash | 52+810%— | 5.7—— | −0.1—— | −43−2320%— | 1.9−97.2%— | 68—— | −3.4r−21−140%— | 8.6+1.5%— | 8.4—— | −3.2—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 157+73.7%— | 28+19.8%— | 25−5.7%— | 59*+122%— | 45+223%— | 23+18.7%— | 27+105%— | 27*+151%— | 14+111%— | 20—— | 13—— | 11*—— | 6.6—— | |
| General and administrative | 22+20.5%— | 6.4+43.6%— | 6.1+31.3%— | 4.6*+2.0%— | 4.6+5.1%— | 4.4−10.0%— | 4.6+22.2%— | 4.6*+29.6%— | 4.3+15.7%— | 4.9—— | 3.8—— | 3.5*—— | 3.8—— | |
| Operating expenses | 179+64.9%— | 34+23.6%— | 31−0.2%— | 64*+105%— | 49+171%— | 28+13.0%— | 31+86.4%— | 31*+121%— | 18+76.7%— | 25—— | 17—— | 14*—— | 10—— | |
| Operating income | −179—— | −34—— | −31—— | −64*—— | −49—— | −28—— | −31—— | −31*—— | −18—— | −25—— | −17—— | −14*—— | −10—— | |
| Other non-operating income (expense) | 6.4−27.1%— | 1.6−2.5%— | 1.5−21.1%— | 1.5*−38.4%— | 1.8−35.4%— | 1.6−45.8%— | 1.9−8.3%— | 2.5*+111%— | 2.8+117%— | 3.0—— | 2.1—— | 1.2*—— | 1.3—— | |
| Income tax | — | — | — | 0*—— | 0—— | 0—— | — | 0*—— | 0—— | 0—— | — | — | — | |
| Net income including minority interests | −173—— | −33*—— | −30—— | −62*—— | −48*—— | −26*—— | −29—— | −29*—— | −15*—— | −22*—— | −15—— | −13*—— | −9.1*—— | |
| Net income attributable to shareholders | −173—— | −33—— | −30—— | −62*—— | −48—— | −26—— | −29—— | −29*—— | −15—— | −22—— | −15—— | −13*—— | −9.1—— | |
| Earnings per share, basic | — | — | — | — | -0.61—— | -0.41—— | -0.46—— | — | -0.24—— | -0.34—— | -0.27—— | — | -0.21—— | |
| Earnings per share, diluted | — | — | — | — | -0.61—— | -0.41—— | -0.46—— | — | -0.24—— | -0.34—— | -0.27—— | — | -0.21—— | |
| Shares, weighted average (basic) | — | — | — | — | 78+22.8%— | 64+0.4%— | 64+19.4%— | — | 64+45.3%— | 64—— | 54—— | — | 44—— | |
| Shares, weighted average (diluted) | — | — | — | — | 78+22.8%— | 64+0.4%— | 64+19.4%— | — | 64+45.3%— | 64—— | 54—— | — | 44—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 93—56.1% | 93+350%56.1% | 178+742%85.3% | 85+157%58.6% | 90+157%48.1% | 21−36.3%13.7% | 21−80.8%12.4% | 33+24.2%16.6% | 35−9.4%16.0% | 32—13.6% | 110—44.4% | 27—27.9% | 39—37.2% | |
| Short-term investments | 64—38.5% | 64−46.1%38.5% | 22−83.5%10.8% | 51−65.8%35.3% | 85−49.4%45.5% | 118−39.1%78.6% | 136+16.4%80.2% | 150+150%75.0% | 169+197%77.0% | 194—81.7% | 117—47.2% | 60—62.6% | 57—54.7% | |
| Other current assets | 4.4—2.7% | 4.4−37.4%2.7% | 4.6−42.3%2.2% | 5.2−56.4%3.5% | 7.8−18.4%4.2% | 7.0+38.8%4.7% | 8.0+118%4.7% | 12+250%5.9% | 9.5+230%4.4% | 5.1—2.1% | 3.7—1.5% | 3.4—3.5% | 2.9—2.8% | |
| Current assets | 161—97.2% | 161+10.4%97.2% | 205+23.9%98.3% | 142−27.3%97.4% | 183−14.1%97.8% | 146−37.0%97.0% | 165−28.3%97.2% | 195+117%97.5% | 213+117%97.4% | 231—97.5% | 231—93.0% | 90—94.0% | 98—94.7% | |
| Property, plant and equipment | 0.6—0.4% | 0.6−19.8%0.4% | 0.6−34.7%0.3% | 0.6−29.4%0.4% | 0.7−9.0%0.4% | 0.8−5.6%0.5% | 0.9+41.6%0.5% | 0.9+28.8%0.4% | 0.8+29.6%0.4% | 0.8—0.4% | 0.6—0.2% | 0.7—0.7% | 0.6—0.6% | |
| Right-of-use (leased) assets | 3.1—1.8% | 3.1+23.8%1.8% | 1.9−29.5%0.9% | 2.1−27.1%1.4% | 2.3−25.0%1.2% | 2.5−23.2%1.6% | 2.6−9.3%1.6% | 2.8−7.8%1.4% | 3.0+4.4%1.4% | 3.2—1.4% | 2.9—1.2% | 3.1—3.2% | 2.9—2.8% | |
| Total assets | 165—100% | 165+10.2%100% | 209+22.5%100% | 146−27.2%100% | 187−14.5%100% | 150−36.8%100% | 170−31.4%100% | 200+109%100% | 219+111%100% | 237—100% | 248—100% | 96—100% | 104—100% | |
| Accounts payable | 7.6—4.6% | 7.6+82.2%4.6% | 8.6+277%4.1% | 5.2+115%3.6% | 11+558%5.9% | 4.2+42.9%2.8% | 2.3+18.6%1.3% | 2.4+88.9%1.2% | 1.7+123%0.8% | 2.9—1.2% | 1.9—0.8% | 1.3—1.3% | 0.8—0.7% | |
| Current liabilities | 34—20.7% | 34+28.2%20.7% | 48+116%22.9% | 65+166%44.4% | 45+177%24.1% | 27+26.0%17.8% | 22+72.4%13.0% | 24+156%12.2% | 16+148%7.4% | 21—8.9% | 13—5.2% | 9.5—9.9% | 6.6—6.3% | |
| Lease liabilities (non-current) | 3.8—2.3% | 3.8+7.7%2.3% | 2.7−27.8%1.3% | 3.0−27.0%2.0% | 3.2−26.3%1.7% | 3.5−24.3%2.3% | 3.8−16.6%2.2% | 4.1−13.8%2.0% | 4.3−7.4%2.0% | 4.6—1.9% | 4.5—1.8% | 4.7—4.9% | 4.7—4.5% | |
| Total liabilities | 38—22.9% | 38+25.8%22.9% | 50+94.9%24.2% | 68+138%46.5% | 48+134%25.8% | 30+17.0%20.1% | 26+49.2%15.2% | 28+99.9%14.2% | 21+83.5%9.4% | 26—10.9% | 17—7.0% | 14—14.8% | 11—10.8% | |
| Retained earnings | −497—−301% | −497—−301% | −464—−223% | −435—−298% | −372—−199% | −325—−216% | −298—−175% | −269—−134% | −240—−110% | −225—−94.8% | −203—−81.9% | −189—−197% | −176—−169% | |
| Shareholders' equity | 127—77.1% | 127+6.3%77.1% | 158+9.5%75.8% | 78−54.6%53.5% | 139−29.9%74.2% | 120−43.3%79.9% | 144−37.5%84.8% | 172+110%85.8% | 198+114%90.6% | 211—89.1% | 231—93.0% | 82—85.2% | 93—89.2% | |
| Total liabilities and equity | 165—100% | 165+10.2%100% | 209+22.5%100% | 146−27.2%100% | 187−14.5%100% | 150−36.8%100% | 170−31.4%100% | 200+109%100% | 219+111%100% | 237—100% | 248—100% | 96—100% | 104—100% | |
| Shares outstanding | 104—— | 104+62.2%— | 104+62.2%— | 83+30.2%— | 86+34.1%— | 64+0.4%— | 64+0.4%— | 64+45.3%— | 64+45.3%— | 64—— | 64—— | 44—— | 44—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 7.5−7.0%— | 2.1+17.6%— | 2.0+7.9%— | 1.6*−35.4%— | 1.8−8.8%— | 1.8−20.6%— | 1.8−13.8%— | 2.4*+25.7%— | 2.0+7.5%— | 2.3—— | 2.1—— | 1.9*—— | 1.8—— | |
| Cash from operating activities | — | −44*—— | −45—— | — | — | −19*—— | −27—— | −22*—— | −25*—— | −14*—— | −10—— | −9.3*—— | −9.2*—— | |
| Capital expenditure | — | — | — | 0*—— | −0.0*—— | −0.0*—— | −0.0—— | −0.2*—— | −0.1*—— | — | — | — | — | |
| Cash from investing activities | — | −41*−317%— | 29+101%— | — | — | 19*—— | 14—— | 19*—— | 27*—— | −63*—— | −68—— | −2.6*—— | −46*—— | |
| Shares issued | — | — | — | −0.2*—— | — | — | — | 0*—— | — | — | — | — | — | |
| Cash from financing activities | — | −0.4*—— | 108—— | — | — | — | — | 0.0*—— | 0.0*—— | −0.3*—— | 162—— | 0*—— | — | |
| Change in cash | 72—— | −85*—— | 93—— | −4.7*—— | 70*+2424%— | −0.5*—— | −12−115%— | −2.6*—— | 2.8*—— | −78*—— | 83—— | −12*—— | −56*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Larimar Therapeutics, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office | — |
| 🇦🇺 Australia | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Larimar Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Ben-Maimon | $3.5 M | $2.1 M | $1.5 M | $36 |
| 2024Dr. Ben-Maimon | $2.5 M | $2.4 M | $1.3 M | $36 |
| 2023Dr. Ben-Maimon | $3.1 M | $3.3 M | $1.4 M | $42 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Larimar Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Material agreement 2 · Unregistered share sale 2 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Unregistered share saleBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Unregistered share saleBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2020 | $80 M | Private placement after listing | $50 to $250 million | 24 | equity | SEC |
| May 2020 | $82 M | Private placement after listing | $50 to $250 million | 1 | equity | SEC |
| Nov 2012 | $22 M | No. 3 | $10 to $50 million | 4 | equity | SEC |
| Jun 2011 | $6 M | No. 2 | $2 to $10 million | 6 | equity | SEC |
| Feb 2010 | $8 M | No. 1 | $2 to $10 million | 3 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 48% of workforce | Restructuring planSEC 8-K | “The reduction in force includes reducing employees by approximately 48%, and when combined with the reduction in force announced on July 24, 2019 and other attrition in 2019, resul…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Larimar Therapeutics, Inc. compares in Biotechnology
- Market cap$246 M · higher than 47% of 726
- Price / book3.1× · lower than 47% of 534
- FCF yield-46.1% · higher than 26% of 449
- 🇺🇸 Standard BioTools Inc.$245 M
- 🇨🇳 Adagene Inc.$244 M
- 🇺🇸 ALX Oncology Holdings Inc.$243 M
- 🇬🇧 Bicycle Therapeutics PLC$249 M
- 🇺🇸 Lifecore Biomedical, Inc.$243 M
- 🇺🇸 Ocugen, Inc.$251 M
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Larimar Therapeutics, Inc.🇺🇸 | $246 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Larimar Therapeutics, Inc.? Verify and update this profile — free
Show Larimar Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.